“Adalimumab treatment” improves dermatology-specific and general health-related quality of life (HRQoL), as well as reducing work and activity limitations and psoriasis-related symptoms in moderate to severe psoriasis patients.
These are the conclusive findings of a study recently taken place under the leadership of Dennis Revicki from the ‘United BioSource Corporation’. This study involved in the initial […]
